• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy.

作者信息

Barker Kenneth, Koza Shannon, Katsanis Emmanuel, Husnain Muhammad

机构信息

Department of Medicine, University of Arizona, Tucson, AZ, USA.

University of Arizona Cancer Center, Tucson, AZ, USA.

出版信息

Bone Marrow Transplant. 2023 Nov;58(11):1267-1269. doi: 10.1038/s41409-023-02083-4. Epub 2023 Aug 14.

DOI:10.1038/s41409-023-02083-4
PMID:37580398
Abstract
摘要

相似文献

1
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy.低磷血症和输注前血小板减少作为CAR-T治疗后CRS和ICANS的生物标志物。
Bone Marrow Transplant. 2023 Nov;58(11):1267-1269. doi: 10.1038/s41409-023-02083-4. Epub 2023 Aug 14.
2
Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.基于影像学的 CAR T 细胞治疗后毒性和反应模式评估。
Radiology. 2022 Feb;302(2):438-445. doi: 10.1148/radiol.2021210760. Epub 2021 Nov 9.
3
Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.低磷血症纠正可降低 CAR-T 细胞治疗中 ICANS 的发生率和持续时间：一项汇总临床试验分析。
Cancer Res Commun. 2024 Oct 1;4(10):2589-2597. doi: 10.1158/2767-9764.CRC-24-0250.
4
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.嵌合抗原受体 T 细胞治疗淋巴瘤后免疫效应细胞相关神经毒性综合征：预测生物标志物和临床结局。
Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183.
5
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.EASIX 和 CD19 导向的 CAR-T 细胞治疗后的严重内皮并发症：一项队列研究。
Front Immunol. 2022 Apr 8;13:877477. doi: 10.3389/fimmu.2022.877477. eCollection 2022.
6
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.嵌合抗原受体T细胞免疫疗法相关神经并发症的简要综述
Neurol Clin. 2020 Nov;38(4):953-963. doi: 10.1016/j.ncl.2020.08.001. Epub 2020 Sep 12.
7
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy.EASIX和m-EASIX可预测CD19嵌合抗原受体T细胞疗法后儿科和青少年及年轻成人患者的CRS和ICANS。
Blood Adv. 2025 Jan 28;9(2):270-279. doi: 10.1182/bloodadvances.2024014027.
8
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.嵌合抗原受体 T 细胞疗法相关免疫效应细胞相关神经毒性综合征。
Front Immunol. 2022 Aug 23;13:879608. doi: 10.3389/fimmu.2022.879608. eCollection 2022.
9
The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.CRS 和 ICANS 对抗 CD19 CAR-T 治疗 B 细胞急性淋巴细胞白血病疗效的影响。
Front Immunol. 2024 Sep 27;15:1448709. doi: 10.3389/fimmu.2024.1448709. eCollection 2024.
10
Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.嵌合抗原受体（CAR）T 细胞输注后无免疫效应细胞脑病（ICE）评分恶化的神经毒性鉴定。
Biol Blood Marrow Transplant. 2020 Nov;26(11):e271-e274. doi: 10.1016/j.bbmt.2020.07.031. Epub 2020 Jul 29.

引用本文的文献

1
Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression.在改良EASIX评分中加入磷和白细胞介素-6可改善对免疫效应细胞相关神经毒性综合征（ICANS）和细胞因子释放综合征（CRS）的检测，以及CRS进展情况的检测。
Cancers (Basel). 2025 Mar 7;17(6):918. doi: 10.3390/cancers17060918.
2
Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.低磷血症纠正可降低 CAR-T 细胞治疗中 ICANS 的发生率和持续时间：一项汇总临床试验分析。
Cancer Res Commun. 2024 Oct 1;4(10):2589-2597. doi: 10.1158/2767-9764.CRC-24-0250.

本文引用的文献

1
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy.由于效应细胞代谢活性增加导致的低磷血症与 CD19 靶向 CAR T 细胞治疗中的神经毒性症状相关。
Cancer Immunol Res. 2022 Dec 2;10(12):1433-1440. doi: 10.1158/2326-6066.CIR-22-0418.
2
Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy.血清磷酸盐水平降低是预测嵌合抗原受体T细胞疗法中细胞因子释放综合征发生和严重程度的有用生物标志物。
Br J Haematol. 2023 Jan;200(1):e1-e3. doi: 10.1111/bjh.18504. Epub 2022 Oct 11.
3
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
用于预测 CD19 靶向 CAR T 细胞治疗后细胞因子释放综合征的生物标志物。
J Immunol. 2021 Apr 1;206(7):1561-1568. doi: 10.4049/jimmunol.2001249. Epub 2021 Mar 10.
4
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.与嵌合抗原受体T细胞疗法相关的细胞因子释放综合征和神经毒性的生物标志物。
Biomark Res. 2018 Jan 22;6:4. doi: 10.1186/s40364-018-0116-0. eCollection 2018.
5
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.CD19嵌合抗原受体修饰的T细胞疗法后严重细胞因子释放综合征的动力学及生物标志物
Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.
6
Signaling and functions of angiopoietin-1 in vascular protection.血管生成素-1在血管保护中的信号传导与功能
Circ Res. 2006 Apr 28;98(8):1014-23. doi: 10.1161/01.RES.0000218275.54089.12.